A major European weight-loss drug company has unexpectedly reported negative news.
Today, during the European trading session, shares of the weight-loss drug giant Novo-Nordisk A/S plummeted, with a sharp decline of over 15% at one point, and in pre-market trading on the US stock market,$Novo-Nordisk A/S (NVO.US)$the stock price also plunged by more than 14%. In terms of news, the experimental results of the company’s next-generation weight-loss drug CagriSema were inferior to those of Zepbound from an American company.$Eli Lilly and Co (LLY.US)$Eli Lilly and Co’s product outperformed in this comparison.
It is worth mentioning that this year, Novo-Nordisk A/S has faced a series of setbacks. The company’s previously released 2026…
